Asrani Sumeet K, O'Leary Jacqueline G
Division of Hepatology, Baylor University Medical Center, 3410 Worth Street, Suite 860, Dallas, TX 75246, USA.
Division of Hepatology, Hepatology Research, Annette C. & Harold C. Simmons Transplant Institute, Baylor University Medical Center, 3410 Worth Street, Suite 860, Dallas, TX 75246, USA.
Clin Liver Dis. 2014 Aug;18(3):561-74. doi: 10.1016/j.cld.2014.05.004.
The Model for End-Stage Liver Disease (MELD) has been the single best predictor of outcome of the progression of cirrhosis. Acute-on-chronic liver failure (ACLF) has been proposed as an alternative path in the natural history of cirrhosis. ACLF occurs in patients with chronic liver disease and is characterized by a precipitating event, resulting in acute deterioration in liver function, multiorgan system failure, and high short-term mortality. In this review, the natural course of patients with ACLF, especially as it relates to management of cirrhotic patients on the transplant waiting list, and its impact on liver transplantation outcomes are defined.
终末期肝病模型（MELD）一直是肝硬化进展预后的最佳单一预测指标。急性慢性肝衰竭（ACLF）已被提出作为肝硬化自然病程中的另一条发展路径。ACLF发生于慢性肝病患者，其特征为有一个促发事件，导致肝功能急性恶化、多器官系统衰竭以及高短期死亡率。在本综述中，定义了ACLF患者的自然病程，尤其是其与移植等待名单上肝硬化患者管理的关系，以及它对肝移植预后的影响。
